Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 46 results for hyperplasia

  1. NICE encourages further research and publication of results from consecutive case series of patients having this procedure. Details of patient selection should be clearly documented. Reported outcomes should include the effects of the procedure on symptoms and quality of life, the duration of benefits, and the need for further procedures. All complications should be reported. NICE may review this procedure in the light of longer-term outcomes.

    implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia is adequate to support the use of this...

    Research recommendation
    Published
    9 June 2015

  2. Further evidence to address uncertainties about the relative clinical and cost effectiveness of UroLift compared with Rezum, especially in the NHS, would be welcome. This should include: • exploring long-term clinical outcomes and reintervention rates after UroLift • assessing the suitability of UroLift for prostates larger than 80 ml and for those with an obstructive median lobe.

    UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia Number MTG58 Date issued May 2021 Other details

    Research recommendation
    Published
    10 August 2021

  3. Thyroid cancer: assessment and management (NG230)

    This guideline covers diagnosis and management of thyroid cancer in people aged 16 and over. It aims to reduce variation in practice and increase the quality of care and survival for people with thyroid cancer.

    NICE guideline
    Published
    19 December 2022
    View recommendations

    Sections for NG230

  4. SonoVue (sulphur hexafluoride microbubbles) – contrast agent for contrast-enhanced ultrasound imaging of the liver (HTG291)

    Evidence-based recommendations on SonoVue (sulphur hexafluoride microbubbles) for contrast-enhanced ultrasound imaging of the liver.

    HealthTech guidance
    Published
    29 August 2012
    View recommendations

    Sections for HTG291

  5. Memokath-028, 044 and 045 stents for urethral obstruction (MIB123)

    NICE has developed a medtech innovation briefing (MIB) on Memokath-028, 044 and 045 stents for urethral obstruction .

    Medtech innovation briefing
    Published
    2 October 2017

  6. Rezum for treating benign prostatic hyperplasia (MIB158)

    This advice has been updated and replaced by NICE medical technologies guidance 49. 

    Medtech innovation briefing
    Published
    24 August 2018

  7. Prostate artery embolisation for benign prostatic hyperplasia (IPG453)

    This guidance has been updated and replaced by NICE interventional procedures guidance 611.

    Interventional procedures guidance
    Published
    26 April 2013

  8. GreenLight XPS for treating benign prostatic hyperplasia (MTG29)

    This guidance has been updated and replaced by NICE healthtech guidance 650.

    Medical technologies guidance
    Published
    14 June 2016

  9. GreenLight XPS for treating benign prostatic hyperplasia (MTG74)

    We have moved Medical technologies guidance 74 to become HealthTech guidance 650. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Medical technologies guidance
    Published
    29 November 2022

  10. Lower urinary tract symptoms secondary to benign prostatic hyperplasia: tadalafil (ESNM18)

    This evidence summary has been updated and replaced by NICE guideline CG97.

    Evidence summary
    Published
    23 May 2013

  11. UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia (MTG26)

    This guidance has been updated and replaced by NICE healthtech guidance 578.

    Medical technologies guidance
    Published
    16 September 2015

  12. UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia (MTG58)

    We have moved Medical technologies guidance 58 to become HealthTech guidance 578. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Medical technologies guidance
    Published
    4 May 2021

  13. Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia (MTG49)

    We have moved Medical technologies guidance 49 to become HealthTech guidance 545. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Medical technologies guidance
    Published
    24 June 2020

  14. Transurethral water jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia (IPG629)

    This guidance has been updated and replaced by NICE interventional procedures guidance 770.

    Interventional procedures guidance
    Published
    19 September 2018

  15. Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia (IPG641)

    This guidance has been updated and replaced by NICE interventional procedures guidance 737.

    Interventional procedures guidance
    Published
    30 January 2019